4,901 trials
Ganglioneuroblastoma · Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma
Primary: Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131 — 86.8 Percentage of participants
Malignant Melanoma · Colorectal Carcinoma
Primary: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 on Day 1 - Dose Escalation: Original Formulation — 2.02; 3.28; 4.47; 4.23 ug*hr/mL
Acute Respiratory Distress Syndrome
Primary: Incidence of Pre-specified Infusion Associated Adverse Events — 0; 0; 0 participants
Healthy Subjects
Primary: Maximum Plasma Concentration (Cmax) of Infacort vs Hydrocortisone — 601.843; 622.384 nmol/L
Renal Impairment · Hepatic Impairment
Primary: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Form of TAK-272 (TAK-272F) and Its…
Vaginismus
Primary: Ability to Achieve Pain Free Intercourse. — 90.3 percentage of participants
Idiopathic Parkinson's Disease
Primary: Maximum Percent Change From Baseline in Movement Disorder Society-Sponsor Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Day 7…
Cannabis Toxicology
Primary: Delta-9-tetrahydrocannabinol (THC) Cmax in Blood — 1.4; 3.07; 0.5 ng/mL
Lean · Obese · Obese Diabetics
Primary: Leptin Signaling — 3.1 fold change
Advanced Malignant Solid Tumors
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Dextromethorphan and Dextrorphan 3 Days Prior to PF-00299804 Dosing — 206.4; 2199…
Prostate Cancer · Bone Metastases
Primary: Number of Subjects With Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 subjects
Colorectal Cancer
Primary: Number of Dose-limiting Toxicities (DLTs) — 0; 1 DLT
Malaria
Primary: Number of Participants With Solicited Adverse Events by Immunization and Type — 8; 18; 4; 13 Participants
Neoplasms · Malignant Solid Tumors · Colon Neoplasms
Primary: Number of Participants With Brachyury-Specific T-cell Responses — 1; 0; 4; 1 Participants
HIV Infections
Primary: Number of Participants Who Experienced Grade 3 or Greater, Treatment Related, Adverse Event (AE) — 0; 0 Participants